The midpoint demonstrates ~32% growth YoY, fueled by new Lilly medicines like Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla, approvals of new indications for existing Lilly medicines ...

For instance, multiple FDA approvals, like those for Zepbound and Omvoh, significantly expanded the company's treatment portfolio. Another factor has been the robust financial results, with sales ...

Off the back of the falls, Nationwide became the latest lender to launch a sub-4% deal ... for pension credit after winter fuel payment cut A record number of people have applied for pension ...

The demand for Grand Theft Auto VI is so strong that many gamers have started to plan to cut purchases of other ... with obesity and the approval of Omvoh in the US for moderately to severely ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

More cuts in the UK mortgage market In the UK, we saw competition heating up in the mortgage market as two more lenders launched sub-4% deals ... was for a half point cut - and this took markets ...

Here's how much Humana's top execs made in 2024 © 2025 American City Business Journals. All rights reserved. Use of and/or registration on any portion of this site ...

In UC, Skyrizi faces direct competition from Eli Lilly’s IL-23 inhibitor Omvoh (mirikizumab), approved by the FDA last year, although that isn’t yet approved for Crohn’s disease. The IBD ...